Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
SP Marso, SC Bain, A Consoli… - … England Journal of …, 2016 - Mass Medical Soc
Background Regulatory guidance specifies the need to establish cardiovascular safety of
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
SP Marso, SC Bain, A Consoli, FG Eliaschewitz… - New England Journal …, 2016 - elibrary.ru
BACKGROUND Regulatory guidance specifies the need to establish cardiovascular safety
of new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
of new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
SP Marso, SC Bain, A Consoli… - The New England …, 2016 - europepmc.org
Background Regulatory guidance specifies the need to establish cardiovascular safety of
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
[PDF][PDF] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
SP Marso, SC Bain, A Consoli, FG Eliaschewitz… - N Engl J Med, 2016 - core.ac.uk
BACKGROUND Regulatory guidance specifies the need to establish cardiovascular safety
of new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
of new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
SP Marso, SC Bain, A Consoli… - New England …, 2016 - utsouthwestern.elsevierpure.com
BACKGROUND Regulatory guidance specifies the need to establish cardiovascular safety
of new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
of new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
SP Marso, SC Bain, A Consoli… - The New England …, 2016 - research.regionh.dk
Background Regulatory guidance specifies the need to establish cardiovascular safety of
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
[引用][C] Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
SP Marso, SC Bain, A Consoli… - New England …, 2016 - portalcientifico.universidadeuropea …
BACKGROUND Regulatory guidance specifies the need to establish cardiovascular safety
of new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
of new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
SP Marso, SC Bain, A Consoli, FG Eliaschewitz… - ikm.ku.dk
BACKGROUND: Regulatory guidance specifies the need to establish cardiovascular safety
of new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
of new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
[引用][C] Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
SP Marso, SC Bain, A Consoli… - NEW ENGLAND …, 2016 - research.unipd.it
[PDF][PDF] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
SP Marso, SC Bain, A Consoli, FG Eliaschewitz… - 2016 - siditalia.it
BACKGROUND Regulatory guidance specifies the need to establish cardiovascular safety
of new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
of new diabetes therapies in patients with type 2 diabetes in order to rule out excess …